Gara Jalqabaatti › Saree Oljoo › North Carolina › Durham
Qorannoo klinikaalii Saree Oljoo Durham, NC keessatti
Qorannoo 64 Saree Oljoo f Durham fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Vanguard Study: Testing a New Way to Screen for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
A Study of PHST001 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Institute, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University, Durham
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Duke Cancer Network, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Durham VA Medical Center, Durham
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
Radiation Therapy and Thymus Function in Young Women With Breast Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Duke Cancer Center, Durham
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Center, Durham
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Duke Cancer Institute, Durham
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Trial Site, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke University Medical Center, Durham
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- University of North Carolina Medical Center, Chapel Hill · Miili 10 fagaatti
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina Medical Center, Chapel Hill · Miili 10 fagaatti
Identifying Patterns in the Breath of Individuals With Breast Cancer
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Duke University Medical Cente, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Namoota walitti qabaa jiraSadarkaa 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Miili 10 fagaatti
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Namoota walitti qabaa jiraSadarkaa 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Duke Cancer Institute, Durham
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke Cancer Institute, Durham
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Institute, Durham
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke Cancer Institute, Durham
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Duke Cancer Institute, Durham
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Namoota walitti qabaa jiraSadarkaa 2
- Duke University, Durham
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
- University of North Carolina-Hillsborough Campus, Hillsborough · Miili 13 fagaatti
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Optimizing Surgical Decisions in Young Adults With Breast Cancer
Namoota walitti qabaa jira
- Duke Cancer Institute, Durham
A Novel Approach Utilizing Organ Specific Age Proteomics
Namoota walitti qabaa jiraQorannoo ilaalaa
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Weight Management After Cancer for Survivors in Rural Communities
Namoota walitti qabaa jira
- Duke University Medical Center, Durham
Behavioral Pain Intervention for Older Cancer Patients
Namoota walitti qabaa jira
- Duke Cancer Network, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Namoota walitti qabaa jiraSadarkaa 2/3
- Duke Cancer Institute, Durham
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Namoota walitti qabaa jira
- Duke University/Duke Cancer Center, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center, Durham
Planning Grant for TOPS for Breast Cancer Survivors
Namoota walitti qabaa jira
- Duke University, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Namoota walitti qabaa jira
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Study of a Decision Tool for People Considering Breast Reconstruction Surgery
Namoota walitti qabaa jira
- Duke Cancer Institute (Data collection only), Durham
- Duke Cancer Institute (Data collection only), Durham
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Namoota walitti qabaa jiraQorannoo ilaalaa
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Miili 10 fagaatti
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- The University of North Carolina, Chapel Hill · Miili 10 fagaatti
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
Namoota walitti qabaa jiraQorannoo ilaalaa
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
Namoota walitti qabaa jira
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · Miili 10 fagaatti
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Namoota walitti qabaa jiraSadarkaa 2
- The University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Namoota walitti qabaa jiraSadarkaa 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Namoota walitti qabaa jira
- Duke University, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke Cancer Center/ DUMC, Durham
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
Namoota walitti qabaa jiraQorannoo ilaalaa
- UNC, Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Institute, Durham
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
Namoota walitti qabaa jira
- UNC Cancer Hospital, Chapel Hill · Miili 10 fagaatti
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
Namoota walitti qabaa jira
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Namoota walitti qabaa jira
- Duke Cancer Institute, Durham
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
Namoota walitti qabaa jira
- Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
BREAST Choice Decision Tool R21 - AIM2
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- The University of North Carolina, Chapel Hill · Miili 10 fagaatti
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
Namoota walitti qabaa jira
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Chapel Hill · Miili 10 fagaatti
UNC Pleural Fluid Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
- Arlington, VAQorannoo 47
Qorannoo biroo Durham keessatti
- Saree (Gosoota Hunda)Qorannoo 58
- Kansara Qara'a Non-Small CellQorannoo 39
- Myeloma Baay’eeQorannoo 37
- Leukemia Myeloidii HamaaQorannoo 33
- Kansara MetastatikiiQorannoo 33
- Kansarii ProstateQorannoo 32
- Dhibee QaraQorannoo 32
- Kansarii ColorectalQorannoo 28
- Kansarii OvariiQorannoo 27
- Luukemiya Limfoositiikii KeessummaaQorannoo 27
- Cufama OnneeQorannoo 26
- Kansarii PancreasQorannoo 24
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.